Rigel Pharmaceuticals, Inc. (RIGL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)

RIGL 30.65

-2.9%

Nov 3 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mopgcw who wrote (422)	2/3/2009 11:42:20 PM
From: mcbio	Read Replies (1) of 566

It seems a bit ridiculous to me to drop the price target from $34 to $16 just because there's going to be maybe a 6 month delay in a partnership. And I don't think that equates to a 6 month delay in starting the Phase III trials as any given partner would have had to wait until the Phase IIb trials were completed and reported in July and August anyway. Also, I'm not sure how there's "higher risk" now to the program. So they have to wait until after Phase IIb to get a more lucrative deal? That makes plenty of sense. And if you believe the drug will show similar results as the Phase IIa, this is really not much additional risk. Besides, if anything, the program could be viewed as less risky since there are no QT/QTc issues.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next